2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

4:30PM-6:00PM: Abstract Number: 1055

Physical Activity Behavior in Men with Inflammatory Arthritis: A Cross-Sectional Register Based Study of Physical Activity Correlates, Motivators, Barriers and Preferences

ARHP II: Healthcare Disparities and and Psychosocial Impact on Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 1009

Plasmacytoid Dendritic Cells Are Activated in Systemic Sclerosis and Contribute to the Disease By Inducing Ifnα and CXCL4

Innate Immunity and Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 1002

Pneumocystis Jiroveci in Rheumatic Disease: A 20 Year Single-Center Experience

Infection-related Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 1015

Pro-Inflammatory Cytokines Produced By Different Subsets of Peripheral Blood Mononuclear Cells Are Associated with Ro52/TRIM21 Deficiency in Patients with Inflammatory Myopathies

Muscle Biology, Myositis and Myopathies

4:30PM-6:00PM: Abstract Number: 1020

Risk Factors Can Classify Individuals Who Develop Accelerated Knee Osteoarthritis

Osteoarthritis – Clinical Aspects I: Epidemiology and Progression

4:30PM-6:00PM: Abstract Number: 988

Risk of Rheumatoid Arthritis after Transfusion of Blood from Donors Later Diagnosed with Rheumatoid Arthritis: A Retrospective Cohort Study

Epidemiology and Public Health I: Inflammatory Arthritis – Risk and Impact

4:30PM-6:00PM: Abstract Number: 1043

Safety and Efficacy of Intravenous Golimumab in Adult Patients with Active Ankylosing Spondylitis: Results through Week 28

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment II: Axial Spondyloarthritis – Treatment

4:30PM-6:00PM: Abstract Number: 1054

Self-Reported Psychological Impact and Coping Strategies of Men with RA

ARHP II: Healthcare Disparities and and Psychosocial Impact on Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 1016

Soluble BAT-3: A New Biomarker for Antisynthetase Syndrome

Muscle Biology, Myositis and Myopathies

4:30PM-6:00PM: Abstract Number: 1017

Statistical Simulation Using Data from the Foundation for the National Institute of Health/Osteoarthritis Initiative Biomarkers Consortium to Evaluate the Clinical Utility of Prognostic Knee Osteoarthritis Biomarkers in Designing a Knee Osteoarthritis Clinical Trial

Osteoarthritis – Clinical Aspects I: Epidemiology and Progression

4:30PM-6:00PM: Abstract Number: 1040

Stressful Life Events : A Trigger for Rheumatoid Arthritis Onset within a Year. a Case-Control Study

Rheumatoid Arthritis – Clinical Aspects I: Pre-RA and Progression to Rheumatoid Arthritis

4:30PM-6:00PM: Abstract Number: 1000

Subclinical Cytomegalovirus Viremia Is Associated with Increased Nosocomial Infections and Prolonged Hospitalization in Patients with Systemic Autoimmune Diseases

Infection-related Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 1024

Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of a Phase 3, Open-Label Clinical Trial

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis

4:30PM-6:00PM: Abstract Number: 1030

Synovial Tissue Resident Macrophages Play the Protective Role in the Development of Inflammatory Arthritis in CD11c-Flip-KO Mice

Rheumatoid Arthritis – Animal Models I

4:30PM-6:00PM: Abstract Number: 1033

Targeting Notch-Activated M1 Macrophages Attenuates Joint Tissue Damage in a Mouse Model of Inflammatory Arthritis

Rheumatoid Arthritis – Animal Models I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].